Added to YB: 2025-07-07
Pitch date: 2025-05-19
XGN [bullish]
Exagen Inc.
+14.83%
current return
Author Info
No bio for this author
Company Info
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Market Cap
$204.2M
Pitch Price
$6.34
Price Target
18.00 (+147%)
Dividend
N/A
EV/EBITDA
-21.18
P/E
-9.59
EV/Sales
3.09
Sector
Biotechnology
Category
turnaround
Exagen Inc. - $XGN
XGN: Molecular diagnostics co for autoimmune diseases. AVISE CTD test 2x more effective than standard care, reducing diagnosis time from 6 years, saving costs. Near breakeven after $35M annual burn. New CEO (sold previous cos), joined by proven turnaround CFO. 1.9x revenue vs peers 4.4x. 20%+ rev CAGR path, profitable by Q4 2025. $16-18 PT (2.5-3x upside).
Read full article (7 min)